Hemab Therapeutics Holdings, In
COAG
Positions held
Your positionsCOAG isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Hemab Therapeutics is positioned in the biotechnology sector, focusing on innovative therapies that address significant unmet medical needs, which could lead to substantial market opportunities.
- The company has a current ratio of 35.847, indicating strong liquidity and the ability to cover short-term liabilities.
- Despite recent losses, Hemab's market cap stands at approximately $1.33 billion, reflecting investor interest and potential growth.
- The company has reported consecutive quarterly net income losses, with -24.15 million in Q2 2026 and -22.687 million in Q1 2026, indicating ongoing financial challenges.
- Hemab has not generated any revenue in the last several quarters, with a total net income loss of -63.913 million for the year 2025.
- The stock has a 'Strong Sell' signal with a score of -16.00, suggesting significant bearish sentiment among analysts.
Fundamentals
| Market cap | $1.44B | Enterprise value | $986.50M | Trailing P/E | — | Forward P/E | -12.17 |
| PEG | — | Price / book | 3.18 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.00 |
| Current ratio | 35.85 | Free cash flow | — | Analyst recommendation | none | Mean target | $61.20 |
| 52w high | $55.42 | 52w low | $23.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$24.1M | -$22.7M | -$12.2M | -$15.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$26.1M | -$23.6M | -$16.1M | -$16.6M |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$63.9M | -$48.7M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$70.1M | -$50.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
2026-09-24 · Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
2026-09-17 · Hemab Therapeutics Doses First Volunteer in Phase 1 HMB-003 Study
2026-08-11 · Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating
2026-08-11 · Hemab Therapeutics' Q2 Net Loss Narrows
2026-08-11 · Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-13 · Wedbush Raises Price Target on Hemab Therapeutics to $55 From $42, Keeps Outperform Rating
Price (daily)
Full chart · RSI · MACD · patterns